CURRICULUM VITAE

David A. Henderson, M.D., F.A.C.C.

OFFICE LOCATION: Cardiology Associates Research Company (1999-present)
Cardiology Physicians, P.A. (1988-present)
305 Memorial Medical Parkway, Suite 301, Daytona Beach, FL. 32117

EDUCATION:

1972-1976	Marshall University Huntington, West Virginia
1976-1980	West Virginia University School of Medicine Morgantown, West Virginia
1980-1981	Straight Medical Internship Shands Teaching Hospital, University of Florida
1981-1983	Medical Residency Shands Teaching Hospital, University of Florida
1983-1985	Fellowship in Cardiology Baylor University Medical Center Dallas, Texas

MEDICAL LICENSE: Florida (ME0038731)

CERTIFICATION:
1983 American Board of Internal Medicine
1987 Subspecialty Board of Cardiovascular Disease
1999 Interventional Cardiology
2002 Nuclear Cardiology

PROFESSIONAL SOCIETIES:
Fellow- American College of Cardiology
American Medical Association
Volusia County Medical Society
Florida Medical Association
Heart Rhythm Society

HOSPITAL AFFILIATIONS:

1985-Present	Florida Hosp Memorial Medical Center, Daytona Beach, FL
1985-Present	Halifax Health Medical Center, Daytona Beach, Florida

OFFICES HELD:

1993-1995	Chief of Medicine, Florida Hospital Memorial Division
1999-2001	Chief of Staff, Florida Hospital Memorial Division
2002-Present	Chairman of Pharmacy and Therapeutics Committee Florida Hospital Memorial Division
2005-Present	Chairman Facilities and Finance Committee Florida Hospital Memorial Division

***PROCTOR*:** 2010 to Present Clinical Instructor of Cardiology
The Florida State University, College of Medicine
Daytona Beach Regional Campus
1200 W. International Speedway Boulevard,
Building 600, Suite 101
Daytona Beach, FL 32114

ORIGINAL RESEARCH AND PUBLICATIONS

1) Henderson, D.A. and Bowyer, A.F.: Feasibility of Direct Coronary Blood Flow Measurements in Intact Human Subjects. West Virginia Medical Journal. September 1978 (abstract).
2) Henderson, D.A. (et.al.): Hospital Cost Containment: A Little Knowledge Helps. Abstract & Oral Presentation American Federation for Clinical Research. Spring Meeting April 1987. Washington.
3) Henderson, D.A. and Morgan, E.M.: Pneumomediastinum as a Complication of Athletic Competition. Thorax 36 (2): 155. 1981.

RESEARCH ACTIVITY

STEM CELLS

Principal Investigator for Baxter to determine the efficacy and safety of targeted intramyocardial delivery of G-CSF mobilized autologous CD34+ cells for the improvement in total exercise time during standardized exercise testing in subjects with refractory angina pectoris and chronic myocardial ischemia (RENEW)

Principal Investigator for Aastrom the evaluate the efficacy, safety, and tolerability of transendocardial injection of ixmyelocel-T in subjects with heart failure due to ischemic dilated cardiomyopathy

CONGESTIVE HEART FAILURE

Principal Investigator for Pfizer in trial of Effects of Eplerenone vs. Placebo on CV mortality and HF hospitalization in patients with NYHA Class II Chronic systolic HF. (EMPHASIS)

Sub-Investigator for Scios in two clinical trials utilizing intravenous Natrecor in the treatment of decompensated congestive heart failure.

Sub-Investigator for SmithKline Beecham in a clinical trial for the treatment of stable NYHA Class II-III congestive heart failure. (ENCOR)

Sub-Investigator for Bristol-Myer Squibb in a clinical trial evaluating patients with chronic heart failure NYHA Class II-IV. (OVERTURE)

Sub-Investigator for Searle Pharmaceutical in a clinical trial for the treatment of heart failure following an acute myocardial infarction. (EPHESUS)

Principal Investigator for Centocor Phase II clinical trial for the treatment of heart failure Class III or IV evaluating the effects of Infliximab (Remicade) – (ATTACH)

Principal Investigator for St. Jude Medical in a heart failure Class III or IV ventricular resynchronization therapy randomized trial. (VECTOR)

Sub-Investigator for Myogen in an advanced heart failure Class III or IV placebo-controlled phase III clinical trial. (ESSENTIAL)

Sub-Investigator for Otsuka Maryland Research Institute Incorporated, Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure. (EVEREST)

LEFT VENTRICULAR DYSFUNCTION

Sub-Investigator for Norvartis in a clinical trial for treatment of high-risk patients after myocardial infarction. (VALIANT)

PERIPHERAL ARTERY DISEASE

Principal Investigator for Astra Zeneca comparing Ticagrelor with Clopidpgrel treatment on the risk of cardiovascular death, Myocardial Infarction and Ischemic Stroke in patients with established PAD

ACUTE MYOCARDIAL INFARCTION

Principal Investigator for Astra Zeneca in a randomized clinical trial (PLATO) A Study of Platelet inhibition and Patient Outcomes.

Sub-Investigator for Centocor in a clinical trial for the treatment of acute myocardial infarction. (GUSTO V)

ACUTE CORONARY SYNDROME

Principal Investigator for Schering Plough in trial to evaluate safety and efficacy of SCH530348 in addition to standard care in patients with ACS. (TRACER)

Principal Investigator for Schering Plough in trial of Benefit and Safety of Vytorin vs. Simvastatin monotherapy in high risk subjects presenting with ACS. (IMPROVE-IT)

Principal Investigator for Roche Pharmaceuticals in a clinical trial for treatment of patients post acute coronary syndrome. (2nd SYMPHONY)

Sub-Investigator for Bristol Myers Squibb in a clinical trial for treatment of patients post acute coronary syndrome. (PROVE IT)

Sub-Investigator for Aventis open-label enoxaparin versus UFH in subjects who present to the emergency room with ACS. (RESCUE)

Sub-Investigator for AstraZeneca in a 12-Week, Randomized, Open-Label, 3-Arm, Parallel Group, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20 mg and 40 mg with that of Atorvastatin 80 mg in Subjects with Acute Coronary Syndromes. (LUNAR)

Principal Investigator for Eli Lilly in a Comparison of CS-747(Prasugrel) and Clopidogrel in Acute Coronary

Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention/TIMI-38 (TRITON)

Principal Investigator for Eli Lilly and Company in a comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome. Subjects with Unstable Angina/Non – ST – Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed (TRILOGY)

Principal Investigator for Johnson & Johnson in a Randomized, Double – Blind, Placebo – Controlled, Event – Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome (TIMI 51)

Principal Investigator for Hoffman La-Roche, Inc. in a Phase III, Double Blind, and Randomized placebo controlled study, to evaluate the effects of dalcetrapib on cardiovascular risk in stable CHD patients, with a documented recent Acute Coronary Syndrome

Principal Investigator for GlaxoSmithKline in a Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (TIMI 52)

ISCHEMIA/STABLE ANGINA

Principal Investigator for Momenta in trial to evaluate safety and efficacy of M118 in PCI in patients with stable CAD (EMMINENCE)

Principal Investigator for Schering Plough in trial to evaluate safety and efficacy of SCH530348 in addition to standard care in patients with atherosclerotic disease. (TIMI 50)

Sub-Investigator for Parke Davis in the treatment of patients with coronary artery disease, silent ischemia, and effort –induced angina. (QUASAR)

Principal Investigator Gilead Sciences GS-US-259-0116 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects with a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention with Incomplete Revascularization (RIVER PCI)

Principal Investigator for Tasly to confirm the anti-anginal effect of T89 in patients with stable angina

ARRHYTHMIAS

Principal Investigator for Sanofi Aventis to evaluate dronedarone vs. amiodarone for maintenance of sinus rhythm in patients with AF (DIONYSOS)

Sub-Investigator for Knoll Pharmaceutical Company in the prevention of symptomatic recurrences of atrial fibrillation. (RAFT)

Principal Investigator for Proctor and Gamble, A Multi-Center, 12-Month Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 75 and 125 mg Doses of Oral Azimilide Dihydrochloride in Patients with an Implantable Cardioverter Defibrillator for the Treatment of Ventricular Arrhythmia. (SHIELD)

Principal Investigator for Proctor and Gamble, A Multi-Center, Open Label, Follow-Up Study to Assess the Long-Term Safety of 125 mg per day of Oral Azimilide Dihydrochloride in Patients with an Implantable

Cardioverter Defibrillator. (SHIELD OPEN LABEL)

Principal Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for the treatment of atrial fibrillation in patients who require electrical cardioversion, with an open-label follow-up phase to assess the long-term efficacy and safety. (A-COMET I)

Principal Investigator for Proctor and Gamble to assess Azimilide Dihydrochloride for prophylactic treatment of atrial fibrillation and an open-label follow-up to assess the long-term efficacy and safety. (A-STAR)

Principal Investigator for Sanofi-Aventis in a Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (ATHENA)

Principal Investigator for Astellas Pharma Global Development, Inc. – Phase IIIb Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in patients with Recent Onset Symptomatic Atrial Fibrillation (ASTELLAS)

Principal Investigator for Sanofi-Aventic U.S. Inc. in a randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors (PALLAS)

Principal Investigator for Daiichi Sankyo Pharma Development in a Phase III, Randomized, Double Blind-Dummy, Parallel Group, Multi – Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b Versus Warfarin in Subjects with Atrial Fibrillation – Effective aNticoaGulation with factor xA Next Generation in Atrial Fibrillation (ENGAGE – AF – TIMI 48)

Principal Investigator for Bayer Healthcare Pharmaceuticals exploring the efficacy and safety of once daily Rivaroxaban compared to VKA for the prevention of Cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion.

ANTI-COAGULANT

Principal Investigator for Sanofi Aventis in a study of safety and efficacy of idraparinux in prevention of stroke and thrombotic events in patients with AF. (BOREALIS)

Principal Investigator for Aryx in a trial of ATI 5923 in comparison with warfarin (EMBRACE AC)

Sub-investigator for Astra Zeneca in a clinical trial to compare an oral direct thrombin inhibitor to dose-adjusted Coumadin in patients with atrial fibrillation. (SPORTIF V)

Sub-Investigator for Boehringer Ingelheim in a Randomized Evaluation of Long Term Anticoagulant Therapy Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etxilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Centre, Parallel-Group, Non-Inferiority Trial (RELY)

ANTI-PLATELET AGGREGATION

Principal Investigator for Astra Zeneca in a randomized clinical trial (PLATO) A Study of Platelet inhibition and Patient Outcomes.

Sub-Investigator for Bristol-Myers Squibb and Sanofi-Snythelabo, Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. (ACTIVE)

Principal Investigator for AstaZeneca AB in a Randomized, Double-Blind, Placebo controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a background of ASA Therapy in Patients with History of Myocardial Infarction (PEGASUS TIMI 54)

HYPERLIPIDEMIA

Principal Investigator for Schering Plough in trial of Benefit and Safety of Vytorin vs. Simvastatin monotherapy in high risk subjects presenting with ACS. (IMPROVE-IT)

Sub-Investigator for Pfizer in an open-label 8-week treatment clinical trial evaluating Atorvastatin doses in dyslipidemic patients. (AT GOAL)

Sub-Investigator for AstraZeneca in a placebo-controlled, phase III, clinical trial in the prevention of cardiovascular events among subjects with low levels of LDL-C and elevated levels of C-Reactive Protein (JUPITER)

Principal Investigator for the University of Oxford in a (Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification): A large scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (REVEAL)

Principal Investigator for Amgen in a Double Blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in combination with HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects (AMGEN - TIMI 57)

Principal Investigator for Sanofi - long term safety and tolerability of REGN/SAR236553 in high CV risk patients with Hypercholesterolemia not adequately controlled with their LMT.

Principal Investigator for Sanofi to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recent ACS (ODYSSEY OUTCOMES)

Principal Investigator for Amgen to evaluate the safety, tolerability and efficacy of AMG145 on LDL-C in combination with statin therapy in subjects with primary hypercholesterolemia and mixed dyslipidemia (Laplace-2)

Principal Investigator for Amgen assessing the impact of Additional LDL Cholesterol reduction on major cardiovascular events when AMG145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease (Fourier)

CLAUDICATION

Sub-Investigator for Otsuka Pharmaceuticals in a clinical trial to assess the long-term effects of Pletal versus placebo for patients with intermittent claudication secondary to peripheral arterial disease. (CASTLE)

HYPERTENSION

Sub-investigator for Bristol Myers Squibb in a clinical trial of Omapatrilat versus Enalapril in mild-moderate/severe hypertension. (OCTAVE)

LEFT VENTRICULAR HYPERTROPHY

Principal Investigator for Norvartis in a multi-center, randomized, Double-Blind parallel group study to evaluate the efficacy of Lotrel and benazepril/hydrochlorothiazide in the regression of left ventricular hypertrophy by magnetic resonance imaging in patients with high risk hypertension. (ALIVE)

Sub-Investigator for GlaxoSmithKline in a randomized, double-blind, multi-center study comparing the effects of Carvedilol modified release formulation (COREG) and Atenolol in combination with and compared to an Angiotensin converting enzyme inhibitor (LISINOPRIL) on left ventricular hypertrophy. (CLEVER)

PCI STUDIES

Principal Investigator for Schering-Plough in a Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention (TRA)

Principal Investigator for Cordis Corporation in a "Prospective, Randomized, Multi-Center, Double-Blind Trial to Assess the effectiveness and Safety of Different Durations of Dual Anti-Platelet Therapy(DAPT) in Subjects undergoing Percutaneous Intervention with the CYPHER Sirolimus-eluting Coronary Stent (CYPHER Stent)"

Principal Investigator for Regado Biosciences to determine the efficacy and safety of the REG1 anti-coagulation system compared to Bivalirudin

DEVICE TRIALS

Principal Investigator for Tryton Medical to evaluate the Safety and Effectiveness of the Tryton side branch stent used in conjunction with a Drug-Eluting Stent compared to side branch Balloon Angioplasty in conjunction with Drug Eluting Stent in the treatment of de novo Bifurcation Lesions Involving the main branch

Sub Investigator for Cardiovascular Sytems Inc. in a Pivotal Trial to Evaluate the Safety and Efficacy (Performance) of the Diamondback 360 Orbital Artherectomy System in Treating De Novo, Severely Calcified Coronary Lesions (ORBIT II)

METABOLIC SYNDROME STUDIES

Principal Investigator for Sanofi Aventis in a study of Rimonabant for reducing the risk of major CV events in abdominally obese patients with clustering of risk factors. (CRESCENDO)

DIABETES

Principal Investigator for Astra Zeneca in a Multicenter, Randomised, Double –Blind, Placebo-Controlled Phase IV Trial to evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type II Diabetes (SAVOR)

Sub Investigator for Astra Zeneca to evaluate the effect of Dapagliflozin 10mg on the incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in patients with Type II Diabetes (Declare)

CARDIAC GEOMETRY AND FUNCTION

Principal Investigator for Sanofi – Aventis U.S., Inc. in a Placebo – Controlled, Double-Blind, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400mg BID on Cardiac Geometry and Function in Patients with Atrial Fibrillation and Left Atrial Enlargement (Odysseus)

CORONARY HEART DISEASE

Principal Investigator Dal-OUTCOMES 2 A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD) (ROCHE 2)

PACEMAKER DEVICE TRIALS

Investigator for evaluation of St. Jude steroid active fixaton lead.

Investigator for St. Jude VDD pacing system.

Investigator for St. Jude AMPS trial: Atrial fibrillation and mode switching pacemaker study.

Principal Investigator for St. Jude in the TENDRIL FSR 1699T Lead Clinical Study

PUBLISHED ARTICLES:

A Novel Lead Design Reduces Far Field R-Waves (FFRWs) and Decreases the Incidence of Inappropriate Automatic Mode Switch Episodes 10-09-09

Response to Ticagrelor in Clopidogrel Non-responders and Responders and the Effects of Switching Therapies: The RESPOND Study 01/07/2010

PRESENTATIONS:

Cardiology Regional Symposium- May 2014 Daytona Beach FL
Life Expectancy and The Impact of Cardiovascular Therapies and Devices

Cardiology Regional Symposium- May 2013 Daytona Beach FL
Who Benefits From PFO Closures